80% of infants requiring intensive care have received at least one blood transfusion as part of their treatment, and 37% more than two.' Frequent blood transfusions expose the infants to multiple donors. One survey reported that infants who were given more than one transfusion received blood from a mean of 4.9 donors.2 There is increasing anxiety concerning the potential adverse effects of blood transfusions and various methods for reducing the need for blood transfusions in sick premature infants have been investigated. In particular, the role of human recombinant erythropoietin has been the subject of a number of controlled studies: we describe an overview of the efficacy of this form of treatment.
Potential hazards of blood transfusion TRANSFUSION TRANSMITTED INFECTION
The acquisition of transfusion related viral infection is a particular anxiety in premature infants, because of their immunological immaturity and the potential for the full clinical expression of diseases such as hepatitis C or HIV infection later in life. Provision of a "safe" blood supply is largely based on donor screening and self-referral. Blood donors in the United Kingdom are routinely screened for syphilis, hepatitis B surface antigen (HBsAg), antibodies to HIV-1 and -2 and, since 1991, antibodies to hepatitis C virus (HCV). The recent controversy over the introduction of routine HCV screening forcibly reminds us that unrecognised infectious agents may be present in the blood supply before effective screening tests are available. Donors with recently acquired viral infection may also occasionally give blood in the "window period" before developing screen detectable antibodies. Blood for premature infants is also screened for antibodies to cytomegalovirus (CMV). CMV antibody screening reduces the risk of transmission to less than 4%,' but a small proportion of CMV seronegative donors have mononuclear cells which are positive for CMV DNA by the polymerase chain reaction. 4 Similar arguments may apply to other leucocyte associated viruses, such as HTLV I and II (not routinely screened for in the United Kingdom because of their low prevalence in the donor population). r-HuEpo better r-HuEpo worse Figure 1 Odds ratio of the needfor at least one transfusion (95% confidence interval) in 12 trials of r-HuEPO. Odds ratio less than unity represent beneficial effects. Trial size is the total number ofpatients with transfusion data given; meta-analysis assumes a fixed effects model. Randomised infants were excluded from the analysis in three studies. 16 23 25 Strict transfusion criteria were not applied in several. 19 22 26 Publication bias may affect the overview, and setting a minimum number of infants/events for trial inclusion may reduce this bias. As the main aim was to collate information on safety, results from all eligible trials are presented (table 2) . However, publication bias may affect the overview of efficacy, although less weight is given to smaller trials in the meta-analysis.
There was no obvious trend towards increased total mortality in infants treated with r-HuEPO from these studies. Longer term follow up, however, went beyond the sixth month of life in only three studies. No increase in the incidence of neutropenia has been reported. There are conflicting results with respect to septicaemia in three studies.1' 17 24 The studies consistently report that r-HuEPO treatment is associated with some reduction in the proportion of infants transfused (fig 1) . Taken as a whole, there is strong evidence to suggest that rHuEPO reduces the need for blood transfusion (Cochran-MantelHaentzel x2 statistic = 35.2, 1 df; P < 0.0001). This conclusion is unchanged after the exclusion of trials terminated early16 or not analysed by intention to treat.19 23 25 The evidence against homogeneity of treatment effects in the trials is minimal (X2 statistic = 17.3, 11 df; P=0.099). Indeed, after exclusion of the trials terminated early or not analysed by intention to treat, which may show exaggerated effect sizes, there is no evidence of a lack of homogeneity (X2 statistic = 6.8, 7 df; P > 0.1). One of the excluded studies25 was a pilot using only a low weekly dose of r-HuEPO. The conclusions from this overview must be viewed in terms of the fact that all the studies recruited small numbers of infants; only two studies enrolled more than 100 subjects.
Conclusions
Clearly, there is no single strategy which can reduce the exposure of premature infants to blood transfusions. It has been estimated that 90% of all erythrocyte transfusions in neonates are for replacement of iatrogenic losses.28 
